Literature DB >> 30130990

Effectiveness of mobile application for menstrual management of working women in Japan: randomized controlled trial and medical economic evaluation.

Mihyon Song1, Hidenobu Kanaoka2.   

Abstract

AIMS: Hormonal imbalances can affect a woman's physical and mental condition, impacting her daily life and productivity. A mobile application, "Karada-no-kimochi", predicts the menstrual cycle based on recorded data, and provides the information regarding menstruation. This study investigates the effectiveness of the application from health condition and labor productivity loss perspectives, and evaluates its cost-effectiveness for employed women in Japan.
MATERIALS AND METHODS: A randomized controlled trial (RCT) was performed to compare the use of the application and non-intervention in female workers (20-45 years) based on an online survey. A discrete-event model based on the RCT data, published literature, and claims data was used for the cost-effectiveness analysis.
RESULTS: The intervention and non-intervention groups comprised 612 and 914 women, respectively. In the intervention group, the incidences of depression (0.16%) and dysmenorrhea (0.33%) were significantly lower than those of the non-intervention group (0.77% and 1.31%, respectively) in the third month. While labor productivity and absenteeism varied, presenteeism showed almost no change across groups. The quality-adjusted life year in the intervention group was 6.84 (0.07 higher than that in the non-intervention group). By analyzing medical expenses and making assumptions regarding productivity, we estimated that the aggregate of medical expenses, productivity loss, and application fee for the intervention group could be lower than that of the non-intervention group by over JPY 130,000 (USD 1,170, as of December 2017) per individual. LIMITATIONS: The subjects included were willing or relatively willing to use the application. Because all outcomes were based on online surveys, the results depended on the objectivity and preciseness of the reports provided by users, and those with severe symptoms might not provide reports.
CONCLUSIONS: The results suggest that using the application is cost-effective and might reduce the incidence of dysmenorrhea and depression.

Entities:  

Keywords:  I10; I12; Mobile application; O33; cost-effectiveness; menstrual cycle; menstruation-associated symptoms; randomized controlled trial; self-health management

Mesh:

Year:  2018        PMID: 30130990     DOI: 10.1080/13696998.2018.1515082

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  5 in total

1.  Menstrual Cycle Tracking Applications and the Potential for Epidemiological Research: A Comprehensive Review of the Literature.

Authors:  Joelle S Schantz; Claudia S P Fernandez; Z Jukic Anne Marie
Journal:  Curr Epidemiol Rep       Date:  2021-02-20

Review 2.  Cost-Effectiveness of Telemedicine in Asia: A Scoping Review.

Authors:  Aisha Salsabilla; Alifia B Azzahra; Raden I P Syafitri; Woro Supadmi; Auliya A Suwantika
Journal:  J Multidiscip Healthc       Date:  2021-12-29

3.  The cost-effectiveness of digital health interventions: A systematic review of the literature.

Authors:  Andrea Gentili; Giovanna Failla; Andriy Melnyk; Valeria Puleo; Gian Luca Di Tanna; Walter Ricciardi; Fidelia Cascini
Journal:  Front Public Health       Date:  2022-08-11

Review 4.  Trends in Effectiveness of Organizational eHealth Interventions in Addressing Employee Mental Health: Systematic Review and Meta-analysis.

Authors:  Elizabeth Stratton; Amit Lampit; Isabella Choi; Hanna Malmberg Gavelin; Melissa Aji; Jennifer Taylor; Rafael A Calvo; Samuel B Harvey; Nick Glozier
Journal:  J Med Internet Res       Date:  2022-09-27       Impact factor: 7.076

5.  Absenteeism during Menstruation among Nursing Students in Spain.

Authors:  Elia Fernández-Martínez; María Dolores Onieva-Zafra; Ana Abreu-Sánchez; Juan José Fernández-Muñóz; María Laura Parra-Fernández
Journal:  Int J Environ Res Public Health       Date:  2019-12-19       Impact factor: 3.390

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.